{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:01:46Z","timestamp":1777766506015,"version":"3.51.4"},"reference-count":0,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>One of the essential characteristics of intracerebral haemorrhages (ICH) is the occurrence of brain oedema (BE). Matrix metalloproteinase-9 (MMP-9) belongs to the family of proteolytic enzymes connected with zinc, which in brain bleeding or a stroke can induce matrix proteolyse into the neurovascular unit, and increase the BE. The aim of the study was to determine the MMP-9 values in serum, and to assess the degree of correlation with neurological deficit in patients with acute, primary and supratentorial ICH.<\/jats:p>\n                  <jats:p>\n                    <jats:italic>Materials<\/jats:italic>\n                    : The study was prospective and included 62 patients with ICH. The neurological deficit of the patients was evaluated by the National Institute Health Stroke Scale (NIHSS). Serum MMP-9 level was determined by enzyme-linked immune sorbent assay (ELISA). Patients were evaluated in three phases: 1\n                    <jats:sup>st<\/jats:sup>\n                    , 3\n                    <jats:sup>rd<\/jats:sup>\n                    and 7\n                    <jats:sup>th<\/jats:sup>\n                    day following the ICH.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Results<\/jats:italic>\n                    : The mean age of the patients was 64.5 \u00b1 9.4. Within the follow-up period, there was a significant rise of the NIHSS score in the first three days: 11.48 \u00b1 3.7; 13.21 \u00b1 3.78, and a significant rise of serum MMP-9, with greatest values in the third day: 134.7 \u00b1 26.1 ng\/ml (p = 0.000). There was a positive, significant correlation (r = 0.886, p = 0.000) between the serum MMP-9 concentration and the NIHSS score.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusion<\/jats:italic>\n                    : Our study showed that in the first three days of ICH, serum MMP-9 values were rising as well as the neurological deficit and the BE. Determination and evaluation of the MMP-9 in serum is an easy, non-invasive, routine laboratory procedure for the detection and follow-up of BE, and also determines further therapeutic strategy as well as prognosis in these patients.\n                  <\/jats:p>","DOI":"10.2478\/prilozi-2014-0005","type":"journal-article","created":{"date-parts":[[2014,12,11]],"date-time":"2014-12-11T05:13:46Z","timestamp":1418274826000},"page":"39-44","source":"Crossref","is-referenced-by-count":6,"title":["Correlative Study Between Serum Matrix Metalloproteinase 9 Values and Neurologic Deficit in Acute, Primary, Supratentorial, Intracerebral Haemorrhage"],"prefix":"10.2478","volume":"35","author":[{"given":"Dragana","family":"Petrovska-Cvetkovska","sequence":"first","affiliation":[{"name":"University Clinic of Neurology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, R Macedonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalija","family":"Dolnenec-Baneva","sequence":"additional","affiliation":[{"name":"University Clinic of Neurology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, R Macedonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dijana","family":"Nikodijevik","sequence":"additional","affiliation":[{"name":"University Clinic of Neurology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, R Macedonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatjana","family":"Chepreganova-Changovska","sequence":"additional","affiliation":[{"name":"University Clinic of Neurology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, R Macedonia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2014,12,1]]},"container-title":["PRILOZI"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/prilozi\/35\/2\/article-p39.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/prilozi-2014-0005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:34:28Z","timestamp":1777476868000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/prilozi-2014-0005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,1]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,12,1]]}},"alternative-id":["10.2478\/prilozi-2014-0005"],"URL":"https:\/\/doi.org\/10.2478\/prilozi-2014-0005","relation":{},"ISSN":["0350-1914"],"issn-type":[{"value":"0350-1914","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,1]]}}}